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Background

- Atherosclerotic cardiovascular disease remains a
leading cause of death worldwide.
- Per 2019 ACC/AHA guidelines, statin therapy is
first-line for primary prevention of ASCVD in
those with diabetes who are 40-75 years of age.
- A quick review of patient data in epic identified a
care gap for patients with diabetes who were not
compliant with statin recommendations.
- Our team reviewed patients in this care gap in
order to identify barriers to statin compliance.

Measurement and Results: Chart Review

- Barriers such as patient preference, expired
prescriptions, and failure to address were
reviewed.
- Data demonstrated the largest reason for statin
noncompliace was that it was not addressed by
provider.

Aims For Improvement

Aim 1: To understand the root cause(s) for gaps in
statin therapy within a large ambulatory care
practice.
Aime 2: To improve provider awareness of
indications for statin therapy, as recommended by
the ACC/AHA guidelines.
Aim 3: To increase the proportion of patients with
diabetes at our practice that are on statin therapy.
Intervention

- We identified a care gap of 257 patients with
diabetes greater than 40 years old within one
JFMA provider team who were not currently on
statin therapy as of January 2020.
- 70 of 257 patients were randomly selected for
chart review.
- The team carefully reviewed each of these 70
charts and identified reasons for non-compliance
with indication for statin therapy.

Next Steps and Lessons Learned

- Our chart review revealed that 50% of
patients with diabetes who were not on
statin therapy at JFMA did not have statin
therapy appropriately addressed by their
provider.
- Given these findings, we aimed to create an
EHR Better Practice Advisory (BPA) to
prompt providers to review this indication
for statin therapy.
- This BPA has since been created and
implemented within our practice.
- Next steps would include measuring statin
use after BPA rollout to determine whether
alerting providers to this statin indication
improves this care gap.

Challenges in the Era of COVID19

Reason for noncompliance

Number of patients
(Total 70)

Nondiabetic

6

Patient declined

13

Statin not addressed within past 2 yrs 32
Statin expired from medication list

12

Discontinued due to age > 75

1

Provider decision

3

Other

3
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- Given the acute nature of the pandemic,
office priorities and resources were
concentrated on efforts surrounding
COVID19.
- Although barrieres to statin compliance
were identified and a BPA was made,
potential next steps such as changes to MA
rooming process were unable to be explored
during this time.
- As ambulatory practice changes in the postCOVID era, we will need to develop novel
ways to continue our chronic disease
management for our vulnerable patients.

